drugset / Trial / NCT04784897

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897

Phase 2 Completed 120 enrolled Innovation Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants

Timeline

Start
2021-02-22
Primary completion
2021-07-01
Completion
2021-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Brilacidin Other / unclassified Intravenous

Indications